X-linked Severe Combined Immunodeficiency

Immunology·MeSH: X-Linked Combined Immunodeficiency Diseases

Prevalence

5.0 / 100K

10 drugs in development·2 companies·1 clinical trial

Drug Pipeline by Phase

Phase 2(3)

Drug	Company
Base-edited hematopoietic stem and progenitor cells	Structure Therapeutics Inc. (GPCR)
Hematopoietic stem cell transplant	Structure Therapeutics Inc. (GPCR)
Plerixafor	Structure Therapeutics Inc. (GPCR)

Phase 1(5)

Drug	Company
Busulfan	Structure Therapeutics Inc. (GPCR)
Palifermin	Structure Therapeutics Inc. (GPCR)
Palifermin	Merus N.V. (MRUS)
Peripheral Blood Stem Cell Infusion	Structure Therapeutics Inc. (GPCR)
Plerixafor	Merus N.V. (MRUS)

Phase 4(2)

Drug	Company
Filgrastim	Structure Therapeutics Inc. (GPCR)
Pegfilgrastim	Structure Therapeutics Inc. (GPCR)

BioSniper tracks 10 drugs in development for X-linked Severe Combined Immunodeficiency across 2 companies.

There are 1 clinical trial targeting X-linked Severe Combined Immunodeficiency tracked by BioSniper.

The estimated prevalence of X-linked Severe Combined Immunodeficiency is approximately 5.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.